key: cord-0759273-9pcr0sg0 authors: Cock, Ian E.; Van Vuuren, Sandy F. title: The traditional use of southern African medicinal plants for the treatment of bacterial respiratory diseases: A review of the ethnobotany and scientific evaluations date: 2020-07-27 journal: J Ethnopharmacol DOI: 10.1016/j.jep.2020.113204 sha: 32076c4348aef9b0b97f47edaa3b4431655f8249 doc_id: 759273 cord_uid: 9pcr0sg0 ETHNOPHARMACOLOGICAL RELEVANCE: Multiple plant species were used traditionally in southern Africa to treat bacterial respiratory diseases. This review summarises this usage and highlights plant species that are yet to be verified for these activities. AIM OF THE STUDY: : This manuscript reviews the traditional usage of southern African plant species to treat bacterial respiratory diseases with the aim of highlighting gaps in the literature and focusing future studies. MATERIALS AND METHODS: An extensive review of ethnobotanical books, reviews and primary scientific studies was undertaken to identify southern African plants which are used in traditional southern African medicine to treat bacterial respiratory diseases. We also searched for southern African plants whose inhibitory activity against bacterial respiratory pathogens has been conmfirmed, to highlight gaps in the literature and focus future studies. RESULTS: One hundred and eighty-seven southern African plant species are recorded as traditional therapies for bacterial respiratory infections. Scientific evaluations of 178 plant species were recorded, although only 42 of these were selected for screening on the basis of their ethnobotanical uses. Therefore, the potential of 146 species used teraditionally to treat bacterial respiratory diseases are yet to be verified. CONCLUSIONS: The inhibitory properties of southern African medicinal plants against bacterial respiratory pathogens is relatively poorly explored and the antibacterial activity of most plant species remains to be verified. Four diseases account for the majority of bacterial respiratory infections globally. Of these, tuberculosis (caused by Mycobacterium tuberculosis) has the greatest burden and is classified as one of the top ten causes of death globally (Floyd et al., 2018) . This disease is highly contagious and is readily spread via airborne transmission. Indeed, the World Health Organisation (WHO) estimates that more than 10 million people fell ill with tuberculosis in 2018, with 1.5 million people dying from the disease (WHO, 2019a) . Of the people contracting M. tuberculosis infections, only 10% develop the active form of the disease and fall ill (Houben and Dodd, 2016) . Therefore, it is estimated that a pool of 100 million new potentially infective people contracted M. tuberculosis infections in 2018. Bacterial pneumonia is also a considerable cause of mortality and morbidity. Indeed, it is classed as the second highest cause of mortality of any communicable disease (after tuberculosis), with more than 800 000 deaths estimated in 2017 (WHO, 2018) . Diphtheria and pertussis caused similarly high mortality rates prior to the widespread introduction of effective vaccination (Holý et al., 2017) . Vaccines have been particularly effective and the rates of infection and mortality have decreased dramatically. For example, the number of reported cases of diphtheria decreased from >1 million cases in 1980 to approximately 4500 in 2018 (WHO, Cape Town, and reported nearly 60% of the students had latent TB infections (Mahomed et al., 2011) . Both of these studies screened specific groups and these statistics do not necessarily represent the overall prevalence of latent M. tuberculosis infections in the entire southern Africa region and the prevalence in urban regions of southern Africa may be substantially different. The Hanifa et al. study (2009) highlights the prevalence of TB on the mining industry. The conditions under which miners may work constitute ideal conditions for the transmission of M. tuberculosis. Miners often work in enclosed spaces underground for extended periods. If a miner has TB, airborne transmission is highly likely under those conditions. Furthermore, miners often share equipment, which may further facilitate the spread of the bacterium. High density lower socio-economic urban communities also have higher incidences of M. tuberculosis infections than other regions of southern Africa. High density living provides ideal conditions for airborne transmission, thereby increasing the likelihood of person to person transfer. Of concern, antibiotic resistant M. tuberculosis strains are highly prevalent in southern Africa, with >90% of new infections reported to be resistant to several frontline antibiotics (WHO, 2019a) . The high prevalence of resistant M. tuberculosis strains contributes to the overall burden of the disease in the region. Not only is it more difficult to treat the disease in infected people, but this also allows for further transmission of the bacterium. The relatively low level of childhood vaccination uptake in several of the southern African countries also contributes to the levels of TB in the region. The WHO report (2019a) estimates that only 59% of children below five years of age have been immunised against TB in South Africa. This contrasts dramatically with the worldwide vaccination rates where it has been estimated that more than 90% of children below the age of five years have been vaccinated for TB. The low vaccination uptake in South Africa is surprising given the incidence of TB in the region and subsidisation of TB vaccination programs by the South African government. Vaccination is relatively cheap and is generally readily available in most areas of the country. We were unable to find a further breakdown of the vaccination statistics on a geographical and ethnic basis, but it is likely that low levels of uptake in isolated and rural communities skew the statistics for the entire country. Isolated and rural communities often have limited access to clinical care, and when medical care is available, rural populations are often poor and may be unable to afford westernised health care. Instead, rural communities are often reliant on traditional healers. However, encouraging TB vaccination programs may be effective in reducing the infection levels in southern Africa, even amongst non-vaccinated people, by providing 'herd immunity', thereby reducing transmissibility. Not surprisingly, the incidence of M. tuberculosis infections is also higher in health care workers than in the general population, due to their levels of exposure to respiratory pathogens. Indeed, one study estimated that the risk of contracting TB is approximately 2.5 times higher for medical professionals than the general population in several countries with similar socio-economic profiles as southern Africa (Joshi et al., 2006) . Furthermore, that study demonstrated that specific health care sectors have substantially increased risks of contracting TB. In particular, the risks to workers in emergency departments, TB treatment facilities, clinical laboratories, and internal medicine departments were particularly high rates of infection. Within those departments, paramedics, nurses, patient attendants, ward attendants and radiology technicians had substantially increased risks of contracting a M. tuberculosis infection. Whilst that study examined the incidence of TB in the health care sector in other countries, it is likely that similar trends occur in southern Africa. Immuno-compromised people also have higher rates of infection than nonimmunocompromised people. Indeed, the WHO report on TB in the southern African countries (WHO, 2019a) estimated that 59% of individuals diagnosed with TB in 2018 in South Africa also had HIV/AIDS. Of further concern, people with HIV/AIDS had a substantially worse prognosis than the general population, with approximately twice the mortality rate. Whilst the WHO report did not break the data down on the basis of age, it is likely that similar trends would occur in children and in the elderly. Both of these groups have lower immuno-competence than healthy adults. Thus, they are likely to have higher incidences of TB, and higher rates of mortality once they contract a M. tuberculosis infection. However, we were unable to find statistics to support this and further studies are needed for confirmation. The other bacterial respiratory diseases generally follow similar trends to other countries with similar socio-economic profiles. As with other regions of the world, widespread diphtheria and pertussis vaccination programs in children have substantially decreased the incidence of those diseases in southern Africa. Indeed, between January 2008 and March 2015, only four cases of diphtheria were reported in South Africa. An outbreak of diphtheria occurred in South Africa in March 2015, with fifteen confirmed cases in rural Kwa-Zulu Natal, of which four died (Mahomed et al., 2015) . All but four of the infected people were either not vaccinated, or their vaccinations were out of date. The outbreak was rapidly contained and the incidence rates have remained low since. Similarly low rates of infection occurred throughout other southern African countries across the same period. Pertussis is far more common than diphtheria in southern Africa. It is difficult to find incidence statistics for individual countries in southern Africa as the WHO provides figures for the African global region instead. According to the WHO, 14 million cases of pertussis were reported from a population of approximately one billion people, which equates to an infection rate of 1.4% of the population. However, vaccination programs are widespread in South Africa and have a far greater take up rate in southern Africa than in central, eastern and western Africa (WHO, 2019c) , so it is likely that the incidence in South Africa (and other southern African countries) is substantially less than this. Pertussis is substantially more common in children than in adults and is one of the most common diseases in children under five years of age. It also has higher incidences in immuno-compromised people than in the general population. A recent study screened children hospitalised for respiratory illnesses in South Africa and reported that pertussis was the cause of approximately 7% of the cases of respiratory illness (Muloiwa et al., 2016) . The rate was significantly higher in HIV positive children (15.8%) and in HIV exposed but negative children (10.9%) than in HIV unexposed children (5.4%). Notably, there have been marked recent increases in the incidence of pertussis in the WHO African world region. Indeed, the number of reported B. pertussis infections in that region has increased from approximately 1.5 million to over 14 million between 2016 to 2018 (WHO, 2019d) . Although specific figures for South Africa are not available from the WHO, it is likely that it has similar trends for those of the rest of the Africa region. It is likely that decreased rates of pertussis vaccination uptake in recent years may contribute to this trend. Indeed, a recent report by the Centre for Communicable Diseases (2018) reported that pertussis vaccination rates in South Africa had decreased to 66% of the population in 2016, allowing for the resurgence of the disease in the region. Bacterial pneumonia is common in both children and adults in southern Africa and it is the most common cause of hospitalisation in South Africa. Indeed, approximately 12 million children were hospitalised and 1.2 million children died from bacterial pneumonia in 2010 in South Africa (Dept of Paediatrics and Child Health, South Africa, 2019). The same study also reported that bacterial pneumonia is the second most common cause of death in South African adults. The disease is substantially more common in immune-compromised individuals (both children and adults). Pertussis and bacterial pneumonia transmission trends are similar to TB. High density urban living allows for efficient transmission of these diseases, therefore the incidence is higher under those conditions. Unfortunately, we were unable to locate occupation specific statistics as reported for TB and further research is required in that area. However, it is likely that similar trends occur (i.e. higher rates in occupations that require workers to work together in confined spaces such as mining; high rates in health care sector professionals through greater contact with infected people). However, these trends have not been reported for pertussis and bacterial pneumonia and further studies are required to confirm this. Our study aimed to identify southern African plants used traditionally to treat bacterial respiratory diseases in humans. A systematic search was undertaken using a variety ethnobotanical books (Smith, 1888; Watt and Breyer-Brandwijk, 1962 ; Van Hutchings et al., 1996; Von Koenen, 2001; Ngwenya et al., 2003; Wyk et al., 2009) and ethnobotanical reviews (Hulley and Van Wyk, 2017; De Beer and Van Wyk, 2011; Nortje and Van Wyk, 2011; Philander, 2011; Van Wyk, 2008) . Ethnobotanical research articles published prior to June 2020 were also searched via Google-Scholar, Science-Direct, PubMed and Scopus using the following terms as filters, and were searched both alone and as combinations: "South African", "medicinal plant", "traditional medicine", "ethnobotany", "respiratory infection" "tuberculosis", "pneumonia", "bacterial pneumonia", "pertussis", "diphtheria", "whooping cough". All terms were searched alone and as combinations. Each plant species identified by this initial search were subjected to a further literature review to establish the extent (if any) of the scientific research into the efficacy of that species. Specific criteria to filter studies included the terms ethnomedicine, southern African medicinal plants and other key words related to bacterial respiratory infections and the specific pathogens. A screening of publication titles was initially performed, and eligible publications were selected. The abstracts of were then read to ensure that the selected publications met the eligibility criteria. Full text manuscripts were retrieved for all publications that met the eligibility requirements and these were further studied. To meet the eligibility criteria for this study, a publication had to meet the following inclusion criteria: • Only English language publications published prior to June 2020 were used in the preparation of this review. • This study is non-biased and does not have taxonomic preference (although several of the studies we review targeted specific families or genera). • For the ethnobotanical studies, the plant species must be stated to be used against the specific bacterial respiratory diseases examined in this study, rather against generic symptoms. • For the screening studies, preparations prepared from plant extracts must have been screened against at least one of the pathogens responsible for the bacterial respiratory diseases. Alternatively, studies that tested the plant preparations against human or animal models with the bacterial respiratory diseases were also included in this study. • For introduced species to be included in this report, they must either be naturalised or widely cultivated, and there must be documented evidence that they are commonly used by at least one southern African ethnic group to treat viral respiratory disease. Studies with the following criteria were excluded from this study: • Studies where the species identity was in doubt. By necessity, several relatively old publications were searched (e.g. Smith, 1888; Watt and Breyer-Brandwijk, 1962) . Where possible, the species names were confirmed or updated using the Plant List website (http://www.theplantlist.org/). Where a species name could not be definitively verified, that species was omitted from this study. • Only plant species definitively described as being used to treat specific bacterial respiratory diseases are included in this study. Due to symptom similarity with numerous diseases, when a plant was described as being used to treat symptoms consistent with bacterial respiratory diseases without specifying the diseases they are used to treat were excluded from this study. • Whilst plant species that are not native to southern Africa are included in this study, introduced plant species were excluded unless there is evidence of their usage in at least one southern African traditional healing system and their widespread cultivation in southern Africa. • Ethnic grouping that traditionally used the plant species medicinally. Where possible, the common and ethnic names were also collected. • The plant part used and the method of preparation were collected (where available). • For screening studies, the bacterial pathogen species and (where possible) the strain were listed and the MIC values (where available) are included. • For animal and human trial studies, the animal model (where appropriate), route of administration, doses and toxicity data (where available) was noted. All data was managed using Excel® software. One hundred and eighty-seven southern African plants which are used in at least one southern African traditional healing system to treat bacterial respiratory infections were identified following an extensive literature search (Table 1) . As indicated in our review of southern African plants to treat viral respiratory infections (Cock and Van Vuuren, part one), several pathogenic respiratory diseases exhibit generic symptoms that are common with other bacterial diseases, as well as viral respiratory diseases. For example, the early stage symptoms of TB are often similar to those of influenza or severe acute respiratory syndrome (SARS). Similar symptoms are also evident for numerous other non-respiratory diseases including bubonic plague, Lyme disease, malaria, measles, rabies, and the early phases of AIDS. As ethnobotanical texts may report the usage of plant species to treat the symptoms of a disease, the specific disease treated is often not definitive. For this study, we have only included plant species that have specifically been reported for the treatment of bacterial respiratory infections in humans. Where the disease pathogen targeted by a plant is ambiguous, we have excluded that species from this study. Thus, it is likely that this list underestimates the number of plant species used to treat bacterial respiratory disease. The relatively high number of plant species used to treat bacterial respiratory diseases may relate to the seriousness and relative prevalence of these infections. Indeed, the vast majority of the plants recorded for use against bacterial respiratory infections were used against bacterial pneumonia (139 species) or TB (81 species). Both of these diseases are relatively common in southern Africa and produce relatively high mortality rates. It is therefore perhaps not surprising that high numbers of plant species were identified for the treatment of these diseases. Many of the ethnobotanical books, reviews and primary studies used in this review did not specify the preparation of the traditional medicine or how it was used and further studies are required to clarify this. However, many of the recent ethnobotanical surveys did report these details, further emphasising the importance of updated ethnobotanical information. From those studies, a further trend was also evident: decoctions and infusions were most widely used in the treatment of bacterial respiratory infections, with 64 plantbased medicines reported to be used in these ways. Previous studies have also reported that decoctions and infusions are the most common methods for treating most pathogenic diseases (Afolayan et al., 2014; Asong et al., 2019; Cock et al., 2018; Cock et al., 2019; de Beer and Van Wyk, 2011; Hulley and Van Wyk, 2017; Nortje and Van Wyk, 2011; Philander, 2011) . Tinctures were prepared and consumed for a further four species, volatiles targeted from three species via inhalation, and a syrup was prepared and consumed from the fruit of various species. This contrasts dramatically with the preparation and usage of plant species to treat viral respiratory diseases, where inhalation was the main method of administration (unpublished results). The use of southern African plants to treat viral respiratory plants will be the basis of another manuscript in preparation. Figure 1 ) were traditionally used to treat bacterial respiratory diseases. Although the bioactivity of several of these species has already been screened against bacterial respiratory pathogens via in vitro testing (Table 2) , most species are yet to be screened against respiratory bacterial pathogens. Asteraceae (33 species) and Fabaceae (20 species) were commonly used traditionally to treat bacterial respiratory diseases ( Figure 1 ). Lamiaceae (9 species), Asparagaceae (9 species), Apocynaceae (8 species plant species were also used to treat several bacterial respiratory diseases, whilst bark (15 species) and stems and twigs (10 species) were also relatively widely used. In contrast flowers, fruit and seeds were only rarely used to treat bacterial respiratory disease. In contrast, the whole plant of some species was used therapeutically in southern African traditional medicine. Complete ethnobotanical records were not available for 36 plant species and we were therefore not able to determine the part used traditionally to treat bacterial respiratory diseases. Whilst the ethnobotanical usage of many southern African plants to treat bacterial respiratory infections are yet to be scientifically evaluated, 189 southern African plant species have been screened for the ability to inhibit the growth of bacterial respiratory infections (Table 2) . Interestingly, only 42 species (indicated in bold within Eloff, 1999) and therefore these species are good candidates for testing. Traditional herbal medicines are promising sources of potential new antibacterial chemotherapeutics. In many cases, their use has been documented for hundreds (or even thousands of years), aiding in species selection for study. Southern African traditional plant use has particularly good potential as there are high biodiversity levels and relatively good records of plant use. Through extensive review of the available ethnobotanical literature, we identified 187 plant species that are used in one or more southern African healing systems to treat either TB, diphtheria, pertussis or bacterial pneumonia. Surprisingly given the ease of transmission and severity of these diseases, only 42 of the identified species have been screened against bacterial causes of these diseases. All of those species were reported to be effective against one or more bacterial respiratory pathogens. However, the other 145 species identified as traditional treatments for respiratory diseases of bacterial origin remain to be screened Even when a plant species has been screened against a bacterial respiratory pathogen, they were usually only tested against one or two pathogens. The plants have been most extensively tested against TB and pneumonia causing pathogens, because of the ease of transmission and relatively high mortality rates caused by these diseases. However, with a few notable exceptions, those studies screen against bacterial strains that are also susceptible to other conventional antibiotics. Given the high incidence of multiple drug resistant strains Notably, all of the screening studies have only used in vitro models to screen the traditional medicines. We were unable to find any studies that screened the plants in in vivo systems. In vitro modelling is best regarded as an initial step in the developing of new drugs from natural sources. Activity in an in vitro system may not necessarily translate to activity in vivo. A large number of bioavailability issues will influence the activity of a plant preparation in vivo. Where promising activity is detected in vitro, the plant preparations should be rescreened using an appropriate in vivo model organism. Furthermore, pharmacodynamics and pharmacokinetic parameters should be examined so that appropriate doses and treatment regimens can be modelled. Of the plants that have been screened for inhibitory activity against the bacterial respiratory pathogens, few were also tested for toxicity. These plants have often been used therapeutically for hundreds of years and it is possible that researchers assume that they are safe and have therefore not focused on the toxicological aspects of the traditional medicine. Many of these plants have been screened for toxicity in other studies (Fennell et al., 2004; Steenkamp and Gouws 2006; ) . However, the focus of those studies was solely on evaluation of toxicity of the extracts, or on investigating the safety of the extracts in conjunction with different bioactivities. Toxicological screening studies should be performed in parallel with therapeutic screening studies to allow the safety index to also be reported. Differences in the methods used to process the plants, as well as differences between collection locations, seasons of collection etc. may result in substantial differences between phytochemical profiles of the different preparations. This may significantly alter their toxicity profiles of the different preparations. It may therefore not be valid to assume that the toxicity profile reported in one study also indicates that bioactive extracts in another study will also be safe. Instead, toxicity evaluations and bioactive screening studies should be included in the same report. Furthermore, to allow for comparisons between different studies, toxicity evaluations should ideally incorporate more than one toxicity model. In conclusion, despite ethnobotanical records of a substantial number of southern African plant species used to treat bacterial respiratory diseases, many are yet to be tested for inhibitory activity against any repiratory bacterial pathogen and substantially more work is need in this field. Indeed, one One hundred and eighty-seven southern African plant species are recorded as traditional therapies for bacterial respiratory infections. Scientific evaluations of 178 plant species were recorded. Of the species evaluated for therapeutic properties, only the potential of 146 species used teraditionally to treat bacterial respiratory diseases are yet to be verified. Furthermore, the species that have been tested against some bacterial respiratory pathogens generally have only been tested against one a few bacteria respiratory pathogens and testing against other bacteria is required. Furthermore, most plant species have only been tested against antibiotic-sensitive pathogen strains. Given the rapid development of antibiotic resistance, the southern African plant species identified in our study should also be screened against antibiotic resistant bacterial strains. Whilst substantial effort is required to screen southern African plants against respiratory bacterial pathogens, a directed approach is recommended. Plant preparations should initially be screened against the pathogens for which they were traditionally used. Furthermore, testing against the pathogens that cause the more serious respiratory diseases (tuberculosis, bacterial pneumonia) is recommended to decrease the burden caused by these diseases. Diphtheria and pertussis are less of a concern than tuberculosis and pneumonia due to the development of effective vaccines against those pathogens. However, they also should not be neglected as the bacteria responsible for these diseases are increasingly evading the vaccines and are concurrently developing resistance to clinical antibiotics. It is hoped that this review will highlight promising species for testing, which may aid in the development of new therapies against bacterial respiratory diseases. Eloff, 1999 Antibacterial activity of 27 southern African members of the Combretaceae Assessing African medicinal plants for efficacy and safety: pharmacological screening and toxicology A rare case of toxigenic diphtheria tonsillitis resistant to penicillin causing sepsis and death The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era Inhibitory properties of selected South African medicinal plants against Mycobacterium tuberculosis Prevalence of latent tuberculosis infection among gold miners in South Africa Prevalence of diphtheria, tetanus and pertussis in the world The global burden of latent tuberculosis infection: a reestimation using mathematical modelling Quantitative medicinal ethnobotany of Kannaland Zulu Medicinal Plants: an inventory, 1 st ed Tuberculosis among health-care workers in low-and middle-income countries: a systematic review Zulu medicinal plants with antibacterial activity Ethnobotanical survey of medicinal plants used in the Maseru district of Lesotho In vitro inhibition of drug-resistant and drug-sensitive strains of Mycobacterium tuberculosis by ethnobotanically selected South African plants In vitro biological activities of South African Pelargonium (Geraniaceae) species Pertussis outbreak in a primary school in China: infection and transmission of the macrolide-resistant Bordetella pertussis Antimicrobial susceptibility testing of Finnish Bordetella pertussis isolates collected during 2006-2017 In vitro antimicrobial activity of extracts from plants used traditionally in South Africa to treat tuberculosis and related symptoms Scientific rationale for traditional use of plants to treat tuberculosis in the eastern region of the OR Tambo district An isolated outbreak of diphtheria in South Africa Predictive factors for latent tuberculosis infection among adolescents in a highburden area in South Africa Isolation and characterisation of antimycobacterial compounds from Schkuhria pinnata (lam.) duntse ex thell against Mycobacterium smegmatis. Doctoral dissertation Phytochemical investigation, antioxidant and antimycobacterial activities of Schkuhria pinnata (Lam) Thell extracts against Mycobacterium smegmatis Activity against Mycobacterium smegmatis and M. tuberculosis by extract of South African medicinal plants The potential of South African plants against Mycobacterium infections Sesotho Plant and Animal Names and Plants Used by the Basotho Epidemiology of diphtheria and antimicrobial resistance among diphtheria cases Pertussis resurgence: waning immunity and pathogen adaptation -two sides of the same coin Detection of amoebaassociated Legionella pneumophila in hospital water networks of Incidence and diagnosis of pertussis in South African children hospitalized with lower respiratory tract infection Potential use of Schkuhria pinnata in the control of Mastitis pathogens Nationwide and regional incidence of microbiologically confirmed pulmonary tuberculosis in Soiuth Africa, 2004-12: a time series analysis Antimicrobial, anti-inflammatory and mutagenic investigation of South African tree Aloe (Aloe barberae) Antibiotic resistance mechanisms in M. tuberculosis: an update Medicinal plants of the Kamiesberg The authors are grateful to the Environmental Futures Research Institute, Griffith University, Australia and the Department of Pharmacy and Pharmacology, University of the Witwatersrand, South Africa and by for the support provided to undertake these studies. (Table 1)